DCAT Value Chain Insights

Tracking Expansions in High-Potency Manufacturing

Driven by growth in oncology drugs, high-potency manufacturing is an active area of investment by CDMOs/CMOs. Which CDMOs/CMOs are making investments? DCAT Value Chain Insights rounds up key recent...

Oncology Pharma Market: Immunotherapies on the Rise

Immunotherapies represent a growing sector in the global oncology pharmaceutical market. Now led by Merck & Co.’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab),...

Overcoming Challenges to Deliver Fixed Dose Combination (FDC) Drug Products

Information
June 2, 2020
Sponsored by Cambrex

With Cambrex’s experience in combining two or more active pharmaceutical ingredients (APIs) into Fixed Dose Combination drugs (FDCs), we are the CDMO that’s expertly positioned to partner with you...

Read More
Q&A with Stephan Haitz, President, CDMO Sales & Marketing at Cambrex

Information
March 9, 2020
Sponsored by Cambrex

Stephan Haitz, President, CDMO Sales & Marketing discusses small molecule trends and how the CDMO industry is constantly evolving to meet the demands and needs of the growing clinical pipeline.

Read More
A Cambrex Webinar- De-Risking the Solid Form Landscape of an API

Information
February 24, 2020
Sponsored by Cambrex

Dr. David Pearson, Chief Scientific Officer of Cambrex Edinburgh, discusses how a full understanding of the crystalline landscape of an active pharmaceutical ingredient (API) molecule can predict...

Read More